Norbudrine (KWD2109) is a sympathomimetic drug. It is an active bronchospasmolytic agent. KWD2109 shows an in vitro bronchospasmolytic acitivity which is about 14 times better than that of KWD2025. In the in vivo tests or guinea pig bronchospasmolytic activity KWD2109 has an effect which is about 3 times that of KWD2025 after intraperitoneal and oral administration

Deterenol is a beta-adrenoceptor agonist. It is an effective nonmydriatic and nonmiotic hypotensive agent, which can be used in antiglaucoma treatment.

Etiprednol dicloacetate (BNP-166; ethyl-17alpha-dichloroacetoxy-11beta-hydroxyandrosta-1,4-diene-3-one-17beta-carboxylate) is a new soft steroid. The compound proved to be a dissociated glucocorticoid, showing a reduction in transactivating activity while preserving transrepressive abilities. The compound effectively decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture. The significant local effect of the compound will very likely be accompanied by a drastically reduced systemic activity indicating an encouraging selectivity of the pharmacological action of etiprednol dicloacetate. Etiprednol dicloacetate had been in a clinical trial for the treatment of allergic rhinitis, asthma and Crohn's disease. However, development has been discontinued.

Vinmegallate (also known as RGH-4417) was developed as a topical dermatological agent for the treatment of psoriasis. Vinmegallate is a phosphodiesterase inhibitor. However, information about the further development of this agent is not available.

Hydromadinone is a steroidal progestin that has never been marketed.

Difenoximide is a water insoluble derivative of diphenoxylate, a chemical congener of meperidine. Difenoximide has been shown to have a greater ability than methadone to suppress opiate withdrawal in addicted mice and it has produced less physical dependence than morphine and methadone in laboratory animals. Since diphenoxylic acid is the major metabolite of both difenoximide and diphenoxylate, it is assumed that difenoximide will have essentially the same dependence liability and long-term toxicologic effects as those of diphenoxylate. Difenoximide has been given to human volunteers and it showed antidiarrheal action without side effects. Difenoximide appeared to be a potentially useful agent for ambulatory narcotic detoxification. The only significant side-effect was constipation.

Oxfenicine is a CPT-1b-specific inhibitor. It must be transaminated to its active form, 4-hydroxyphenyl-glyoxylate, which is competitive with carnitine, preventing the formation of acylcarnitine. Because CPT-1b shows the highest sensitivity to 4-hydroxyphenyl-glyoxylate, inhibition of fatty acid oxidation by oxfenicine takes place selectively in those tissues that express this CPT isoform. It may be effective for treating noninsulin-dependent diabetes mellitus which is characterized by elevated fatty acid levels and obesity. In 1980 it was also tested in preclinical models of angina pectoris and ischemia.

Meteneprost (9-deoxo-16, 16-dimethyl-9-methylene PGE2) is a prostaglandin E2 analog. It exerts uterine-stimulating potency: meteneprost is able to both stimulate uterine contractions and dilate the cervical canal. It was studied as an abortifacient in early pregnancy.

Estrazinol is a synthetic estrogen.

Oximonam (also known as SQ 82,291) was developed as a monobactam antibiotic that had shown good activity against different bacteria of the family Enterobacteriaceae and Haemophilus influenzae and was no activity at all against staphylococci and against Pseudomonas aeruginosa.